What is the kidney adenocarcinoma?

Renal adenocarcinoma is a type of cancer that develops in the kidneys. Between 90 and 95 percent of kidney cancer is this kind; The remaining five to 10 percent are either lymphomas or are cancer metastases that develop elsewhere in the body. Renal adenocarcinoma is known under several other names, including kidney adenocarcinoma, kidney cancer, kidney cancer, kidney and kidney cancer. This type of cancer occurs with greater frequency in people of North European and North American origin than in people of Asian or African origin and is also more common in men than in women. Most people diagnosed with kidney cancer are between 40 and 70 years old. When the disease develops in a younger person, it is usually because it has inherited one or more genes that increase the risks that occur. The side is an area located on the back of the body, between the hips and the ribs. In general, the pain of the side is felt only on one side of the body. Other symptoms of this cancer may include unintentional, inexplicable loss of massOsvat, constipation, unusually pale skin and visual impairment.

Many people with renal adenocarcinoma are diagnosed late during the disease and often cancer before diagnosis has progressed significantly. Less than 10 percent of people experience three classical signs of side pain, side and hematuria. Up to 30 percent of cases are diagnosed only after cancer has spread to other parts of the body.

One of the main risk factors for Rrakovin ENAL is cigarette smoking, estimated to double the risk of this type of cancer. Other risk factors include obesity, hypertension, long -term use of analgesic drug phenotin and a genetic condition called tuberous sclerosis, which causes tumor formation in several places. People with an inherited state called von Hippel-Londau's disease are also exposed to an increased risk of kidney cancer. This type of inherited adenocarcinoma kidneys withE develops in approximately 40 percent of people with von Hippel-Londau disease.

Standard treatment of kidney cancer is surgery to remove kidneys, chemotherapy and radiotherapy. Other possible treatments include immunotherapy and hormonal therapy. The effectiveness of treatment in kidney cancer is much higher in people who are diagnosed early. Only 11 percent of people with metastasized kidney cancer will survive for more than five years after diagnosis, compared to 64 to 66 percent of people with small, not metastasizedminádors.